Xeljanz (tofacitinib): Initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF-alpha inhibitors

Manufacturers highlight that preliminary data from a completed clinical trial in rheumatoid arthritis suggest a higher risk of major adverse cardiovascular events and malignancies vs anti-TNFs. Prescribers are asked to bear in mind when considering risks and benefits of treatment

Source:

Pfizer